BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
120 results:

  • 1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
    Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
    Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
    Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
    Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Establishment and Characterization of Amitrole-Induced Mouse Thyroid Adenomatous Nodule-Derived Cell Lines.
    Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
    Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
    [No Abstract]    [Full Text] [Related]  

  • 4. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
    Zúñiga D; Stumpf MAM; Monteiro ALS; Glezer A
    J Endocrinol Invest; 2024 May; 47(5):1295-1303. PubMed ID: 37938428
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Risk-stratified Distant Metastatic Thyroid cancer with Clinicopathological Factors and BRAF/tert Promoter Mutations.
    Cheng X; Zhou Y; Xu S; Yu H; Wu J; Bao J; Zhang L
    Exp Clin Endocrinol Diabetes; 2023 Nov; 131(11):577-582. PubMed ID: 37922948
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
    Cleere EF; Prunty S; O'Neill JP
    Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing.
    Deng L; Zeng J; Qiu JF; Yang LH; Ma J
    Medicine (Baltimore); 2023 Aug; 102(32):e34523. PubMed ID: 37565864
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid cancer.
    Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
    JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI treatment in the Thyroid cancer ATA Intermediate Risk Category.
    Pizzimenti C; Fiorentino V; Ieni A; Rossi ED; Germanà E; Giovanella L; Lentini M; Alessi Y; Tuccari G; Campennì A; Martini M; Fadda G
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373171
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring tert promoter and BRAF
    Su YJ; Cheng SH; Qian J; Zhang M; Liu W; Zhan XX; Wang ZQ; Liu HD; Zhong XW; Cheng RC
    Arch Endocrinol Metab; 2023 Jun; 67(6):e000659. PubMed ID: 37364156
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.
    Nilsson JN; Siikanen J; Condello V; Jatta K; Saini R; Hedman C; Ihre Lundgren C; Juhlin CC
    Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37352166
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Predictive factors for nodal recurrence in differentiated thyroid cancers.
    Kaur J; Nadarajan A; Janardhan D; George NA; Thomas S; Varghese BT; Krishna J
    Cancer Treat Res Commun; 2023; 36():100728. PubMed ID: 37336036
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
    Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
    Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genetic Considerations in the Tumorigenesis, Diagnosis, and treatment of Differentiated Thyroid cancer: Current State of the Science.
    Richmond BK; Gallimore J
    Am Surg; 2023 Nov; 89(11):4853-4859. PubMed ID: 37253623
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
    Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
    Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
    Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
    BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. BRAF
    Choi JH; Yu HW; Lee JK; Kim W; Choi JY; Na HY; Park SY; Ahn CH; Moon JH; Choi SI; Lee HY; Lee WW; Cha W; Jeong WJ
    World J Surg Oncol; 2023 Feb; 21(1):49. PubMed ID: 36804879
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments.
    Nakanishi K; Fukagawa T; Yamada T; Suzuki S
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593625
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.